Early Morning Activity Shows GlaxoSmithKline (GSK) Down

Trade-Ideas LLC identified GlaxoSmithKline (GSK) as a pre-market laggard candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

GlaxoSmithKline

(

GSK

) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified GlaxoSmithKline as such a stock due to the following factors:

  • GSK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $210.1 million.
  • GSK traded 12,656 shares today in the pre-market hours as of 8:12 AM.
  • GSK is down 2% today from Friday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in GSK with the Ticky from Trade-Ideas. See the FREE profile for GSK NOW at Trade-Ideas

More details on GSK:

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The stock currently has a dividend yield of 5.7%. GSK has a PE ratio of 15. Currently there are 3 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 5 rate it a hold.

The average volume for GlaxoSmithKline has been 3.9 million shares per day over the past 30 days. GlaxoSmithKline has a market cap of $102.2 billion and is part of the health care sector and drugs industry. Shares are down 1.9% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates GlaxoSmithKline as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:

  • GSK's revenue growth has slightly outpaced the industry average of 7.1%. Since the same quarter one year prior, revenues slightly increased by 2.7%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, GLAXOSMITHKLINE PLC's return on equity significantly exceeds that of both the industry average and the S&P 500.
  • The gross profit margin for GLAXOSMITHKLINE PLC is rather high; currently it is at 62.96%. Regardless of GSK's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, GSK's net profit margin of 3.93% is significantly lower than the industry average.
  • GLAXOSMITHKLINE PLC's earnings per share declined by 38.1% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year. During the past fiscal year, GLAXOSMITHKLINE PLC reported lower earnings of $1.77 versus $3.68 in the prior year. This year, the market expects an improvement in earnings ($78.52 versus $1.77).
  • The share price of GLAXOSMITHKLINE PLC has not done very well: it is down 6.34% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. Looking ahead, although the push and pull of the overall market trend could certainly make a critical difference, we do not see any strong reason stemming from the company's fundamentals that would cause a continuation of last year's decline. In fact, the stock is now selling for less than others in its industry in relation to its current earnings.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...